| Not Yet Recruiting | Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC NCT07392073 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Not Yet Recruiting | Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC NCT07309952 | Yang Hong | Phase 2 |
| Recruiting | Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NS NCT06167460 | Gene Solutions | — |
| Completed | Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer NCT06525246 | Ono Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) NCT04776447 | Fundación GECP | Phase 2 |
| Active Not Recruiting | CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell L NCT04062708 | Alliance Foundation Trials, LLC. | Phase 2 |
| Completed | Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consoli NCT03916419 | Washington University School of Medicine | Phase 2 |
| Terminated | Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer NCT03087708 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Unknown | Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That C NCT03048500 | Northwestern University | Phase 2 |
| Completed | Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer NCT02947386 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618 | University of Southern California | Phase 2 |
| Completed | TG4010 and Nivolumab in Patients With Lung Cancer NCT02823990 | Megan Daly, MD | Phase 2 |
| Completed | Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors NCT02897375 | Emory University | Phase 1 |
| Completed | S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) NCT02728596 | SWOG Cancer Research Network | N/A |
| Completed | Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell L NCT02879994 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Smal NCT02621398 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurre NCT02581943 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomog NCT02819024 | Barbara Ann Karmanos Cancer Institute | N/A |
| Withdrawn | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery an NCT02567396 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer NCT02655913 | Clifford Hospital, Guangzhou, China | Phase 1 / Phase 2 |
| Terminated | Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Remove NCT02566421 | Wake Forest University Health Sciences | N/A |
| Completed | Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib NCT02364609 | Jonathan Riess | Phase 1 |
| Active Not Recruiting | Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or NCT02495896 | University of Southern California | Phase 1 |
| Withdrawn | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors NCT01971489 | Roswell Park Cancer Institute | Phase 1 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Completed | Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuita NCT02262325 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Terminated | Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cance NCT02132884 | Fox Chase Cancer Center | N/A |
| Completed | Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non NCT02243748 | City of Hope Medical Center | N/A |
| Withdrawn | Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy NCT02106559 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III NCT02186847 | NRG Oncology | Phase 2 |
| Completed | Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell NCT01958372 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Completed | Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV No NCT02245100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | — |
| Withdrawn | Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer NCT02059889 | Virginia Commonwealth University | N/A |
| Terminated | Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surg NCT02134886 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Ce NCT01737502 | Mayo Clinic | Phase 1 / Phase 2 |
| Withdrawn | Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC NCT02059967 | Virginia Commonwealth University | Phase 1 |
| Completed | Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed b NCT01854684 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients NCT01999881 | University of Wisconsin, Madison | N/A |
| Terminated | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer NCT01857271 | Albert Einstein College of Medicine | Phase 2 |
| Withdrawn | Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Canc NCT02017925 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers NCT01935336 | University of Colorado, Denver | Phase 2 |
| Completed | Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer NCT01839955 | Neelesh Sharma MD PhD | Phase 1 |
| Completed | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stag NCT02073968 | Albert Einstein College of Medicine | Phase 2 |
| Terminated | Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer NCT01935947 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung C NCT01781741 | Roswell Park Cancer Institute | EARLY_Phase 1 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorect NCT01726296 | Fox Chase Cancer Center | N/A |
| Completed | Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer NCT01741636 | City of Hope Medical Center | N/A |
| Terminated | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer NCT01707823 | Vanderbilt-Ingram Cancer Center | EARLY_Phase 1 |
| Unknown | An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC) NCT01711697 | Emory University | Phase 1 |
| Terminated | Circulating Tumor Cells in Lung Cancer NCT01658332 | Central Hospital, Nancy, France | N/A |
| Terminated | Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot B NCT01411098 | University of Washington | Phase 1 |
| Withdrawn | Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer NCT01383668 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination NCT01345851 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer NCT01457469 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Ur NCT01282333 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment NCT01193868 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With NCT00976677 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lun NCT00986674 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-s NCT00738881 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small NCT00778167 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III NCT00662311 | University of Washington | Phase 1 / Phase 2 |
| Completed | AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy NCT00638937 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis NCT01014598 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung NCT00499655 | City of Hope Medical Center | Phase 2 |
| Completed | FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung C NCT00564733 | University of Washington | Phase 2 |
| Completed | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage NCT01557959 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung C NCT00481078 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00459342 | National Cancer Institute (NCI) | Phase 2 |
| Completed | E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00400829 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB NCT00387374 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell L NCT00368992 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer NCT00387465 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Adv NCT00369551 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurre NCT00950365 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Ca NCT00408460 | University of Washington | Phase 2 |
| Completed | Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer NCT00247416 | Susanne Arnold | Phase 2 |
| Completed | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Sta NCT00118183 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer NCT00118144 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lu NCT00138203 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00098540 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer NCT00087412 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer NCT00085280 | National Cancer Institute (NCI) | N/A |
| Completed | Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer NCT00093756 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer NCT00087191 | National Cancer Institute (NCI) | N/A |
| Completed | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With NCT00088088 | Synta Pharmaceuticals Corp. | Phase 1 / Phase 2 |
| Completed | CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer NCT00079235 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer NCT00075751 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer NCT00062101 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00088959 | National Cancer Institute (NCI) | Phase 1 |
| Completed | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-S NCT00074022 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Can NCT00055757 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Can NCT00068497 | National Cancer Institute (NCI) | N/A |
| Completed | Suramin and Either Docetaxel or Gemcitabine in Treating Patients With Stage IIIB or Stage IV Platinum-Refracto NCT00066768 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carc NCT00063895 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer NCT00078390 | Shionogi | Phase 1 / Phase 2 |
| Completed | Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lun NCT00052338 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurr NCT00021060 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Terminated | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carbop NCT00042302 | QLT Inc. | Phase 3 |
| Terminated | A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Vinorelbine as Fi NCT00042315 | QLT Inc. | Phase 3 |
| Completed | EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer NCT02154399 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell NCT00040794 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III N NCT00042835 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer NCT00040768 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer NCT00029003 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III N NCT00020709 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Canc NCT00006929 | National Cancer Institute (NCI) | Phase 2 |
| Completed | FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Can NCT00020202 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non NCT00005838 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER NCT00004883 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Carboxyamidotriazole in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer NCT00003869 | National Cancer Institute (NCI) | Phase 3 |